Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03145870

Prevalence of Asymptomatic Thrombosis in Multiple Myeloma

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Centre Hospitalier Universitaire, Amiens · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Malignant hemopathies, such as solid cancers, increase the risk of venous and arterial thromboembolic events. The incidence of symptomatic venous thromboembolic events is particularly high in myeloma, linked to the usual risk factors for venous thromboembolic disease, biological risk factors specific to myeloma, and especially to its treatments. The prevalence of asymptomatic venous thromboembolic events and arterial events are not known to date and remain important data for planning a possible randomized study to determine the most suitable thromboprophylaxis in these patients.

Conditions

Interventions

TypeNameDescription
OTHEREchoing of the lower limbs and measuring the systolic pressure indexEchoing of the lower limbs and measuring the systolic pressure index

Timeline

Start date
2014-06-03
Primary completion
2017-05-16
Completion
2017-05-16
First posted
2017-05-09
Last updated
2020-07-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03145870. Inclusion in this directory is not an endorsement.

Prevalence of Asymptomatic Thrombosis in Multiple Myeloma (NCT03145870) · Clinical Trials Directory